Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.

ABSTRACT:

Background

Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory effects. Our aim was to identify whether metformin reduced COVID-19-related mortality and whether sex-specific interactions exist.

Methods

In this retrospective cohort analysis, we assessed de-identified claims data from UnitedHealth Group (UHG)'s Clinical Discovery Claims Database. Patient data were eligible for inclusion if they were aged 18 years or older; had type 2 diabetes or obesity (defined based on claims); at least 6 months of continuous enrolment in 2019; and admission to hospital for COVID-19 confirmed by PCR, manual chart review by UHG, or reported from the hospital to UHG. The primary

SUBMITTER: Bramante CT 

PROVIDER: S-EPMC7832552 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature